Forecasted sales for beta-blocking medicines in Germany from 2024 to 2028 indicate a constant value of 9.7 US dollars per capita annually. As we step into 2024, it's essential to note that the value was stable in 2023 as well. The lack of variation from 2024 to 2028 signifies a stagnant market with no anticipated growth or decline across the per capita spending over the forecasted years. This results in a zero percent annual growth rate, pointing towards a plateaued trend over the forecast window.

Future trends to watch for include:

Potential market disruptors like new beta-blocker advancements or alternative treatment options.
Changes in healthcare policies or economic conditions that may influence public spending ability or government support.
Emerging health data that could shift physician prescriptions towards or away from beta-blockers.